Clinical Trials Logo

Coagulation Disorder clinical trials

View clinical trials related to Coagulation Disorder.

Filter by:

NCT ID: NCT04508439 Recruiting - Covid19 Clinical Trials

Effect of the Use of Anticoagulant Therapy During Hospitalization and Discharge in Patients With COVID-19 Infection

Start date: June 20, 2020
Phase: N/A
Study type: Interventional

Viral infections provoke the systemic inflammatory response and cause an imbalance between the procoagulant and anticoagulant homeostatic mechanisms. Multiple pathogenic mechanisms are involved, including endothelial dysfunction, increased von Willebrand factor, Toll receptor activation, and tissue factor pathway activation. D-dimer levels greater than 1000 ng / mL are associated with an 18-fold increased risk of mortality. In this context, many patients may require prophylaxis or antithrombotic treatment with low molecular weight heparins. Currently, there is no validated scheme on the dose and timing of the use of antithrombotic drugs. The study aims to identify the effect of two anticoagulant strategies (prophylactic and therapeutic) on the progression to ventilatory support or death in patients with COVID-19 infection who require hospital care.

NCT ID: NCT04490759 Completed - Clinical trials for Coagulation Disorder

QStat Pilot Reference Range Study

Start date: November 29, 2018
Phase:
Study type: Observational

The objective is to determine the initial reference range intervals for the parameters reported by the Quantra System with the QStat Cartridge.

NCT ID: NCT04488341 Recruiting - Clinical trials for Coagulation Disorder

Effect of Aerobic Exercises on Sex Hormones and Coagulation Factors in Postmenopausal Elderly Women

Start date: September 20, 2020
Phase: N/A
Study type: Interventional

PURPOSE: to determine the effect of aerobic exercise training on sex hormones and coagulation factors in postmenopausal elderly women BACKGROUND: Cardiovascular disease (CVD) is the largest cause of death in women, and the risk of developing CVD increases after menopause . Because thrombosis is thought to be a cause of most acute cardiovascular events, abnormalities in endogenous coagulation and fibrinolysis may play an important role in the risk of an acute cardiovascular event. Aging is also associated with adverse changes in both coagulation and fibrinolysis. For instance, postmenopausal women exhibit higher fibrinogen levels and lower levels of endogenous fibrinolysis. Physical activity and physical fitness have consistently been linked to lower CVD rates in women. In fact, an inverse association between physical activity and total mortality, as well as a 50% reduction in risk of myocardial infarction, has been observed in physically active postmenopausal women. In addition to the numerous other benefits provided by regular physical activity, one of the mechanisms mediating the cardioprotective effect may be changes in the hemostatic system, particularly fibrinolysis HYPOTHESES: Aerobic exercises may have no effect on sex hormones and coagulation factors in elderly postmenopausal women RESEARCH QUESTION: Do aerobic exercises effect on sex hormones and coagulation factors in elderly postmenopausal women in response to exercises?

NCT ID: NCT04479280 Completed - Clinical trials for Coagulation Disorder

Evaluation of Coagulopathy in Critically Ill COVID-19 Patients.

Start date: July 20, 2020
Phase:
Study type: Observational

Novel coronavirus disease 19 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), this pneumonia was first emerged in December 2019 in Wuhan, China and rapidly spread around the world . Coagulopathy is one of the most significant prognostic factors in patients with COVID-19 and is associated with increased mortality and admission to critical care. Most observed coagulopathy in patients hospitalized with COVID-19 (COVID-19-associated coagulopathy) is characterized by increased D-dimer and fibrinogen levels. 71% of patients who did not survive hospitalization reported to have developed disseminated intravascular coagulation

NCT ID: NCT04474249 Recruiting - COVID19 Clinical Trials

Follow-up of Critical COVID-19 Patients

FUP-COVID
Start date: June 25, 2020
Phase:
Study type: Observational

The study will follow COVID-19 patients who required intensive care after 3-6 months and one year after discharge from the ICU with functional level as well as organ function to assess recovery after COVID-19. Blood and urine will be collected for biobanking.

NCT ID: NCT04460664 Completed - COVID Clinical Trials

Coagulation Changes Associated With COVID-19 Infection

Start date: August 14, 2020
Phase:
Study type: Observational

This study will study the potential utility of the Quantra QPlus System in patients inflicted with COVID-19 disease.

NCT ID: NCT04408235 Not yet recruiting - COVID Clinical Trials

High Versus Low LMWH Dosages in Hospitalized Patients With Severe COVID-19 Pneumonia and Coagulopathy

COVID-19 HD
Start date: June 2020
Phase: Phase 3
Study type: Interventional

Randomized, controlled study conducted in hospitalized patients with severe COViD-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation. Aim of this study is to assess whether high doses of Low Molecular Weight Heparin (LMWH) (ie. Enoxaparin 70 IU/kg twice daily) compared to standard prophylactic dose (ie, Enoxaparin 4000 IU once day) are: 1. More effective to prevent clinical worsening, defined as the occurrence of at least one of the following events, whichever comes first, during hospital stay: 1. Death 2. Acute Myocardial Infarction [AMI] 3. Objectively confirmed, symptomatic arterial or venous thromboembolism [TE] 4. Need for either non-invasive - Continuous Positive Airway Pressure (Cpap) or Non-Invasive Ventilation (NIV) - or invasive mechanical ventilation for patients who are in standard oxygen therapy by delivery interfaces at randomisation 5. Need for invasive mechanical ventilation for patients who are in non-invasive mechanical ventilation at randomisation 2. Similar in terms of major bleeding risk during hospital stay

NCT ID: NCT04322721 Completed - Clinical trials for Traumatic Brain Injury

Coagulopathy on the First Postoperative Day Predicts the Long-term Survival of Traumatic Brain Injury Patients

Start date: October 1, 2019
Phase:
Study type: Observational

The purpose of this study was to identify the relationship between coagulopathy during the perioperative period (before the operation and on the first day after the operation) and the long-term survival of traumatic brain injury patients undergoing surgery, as well as to explore the predisposing risk factors that may cause perioperative coagulopathy.

NCT ID: NCT04278404 Recruiting - Hypertension Clinical Trials

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

POPS or POP02
Start date: March 5, 2020
Phase:
Study type: Observational

The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.

NCT ID: NCT04274777 Recruiting - Clinical trials for Traumatic Brain Injury

The Relationship Between Lipid Peroxidation Products From Traumatic Brain Injury and Secondary Coagulation Disorders

Start date: September 21, 2019
Phase:
Study type: Observational

The purpose of this study is to observe the relationship between the level of lipid peroxidation products in serum of patients with traumatic brain injury and secondary coagulation disorders.